YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02224768
Status
Completed

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

Key Dates

Start date
Jul 31, 2015
Status verified
Dec 2015
Primary completion
Nov 30, 2015
Completion
Nov 30, 2015

Study Design

Enrollment
158 participants (actual)

Arms

  • Arm: HCP and Patient inclusion
    HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials

Primary Outcome Measure

The proportion of YERVOY HCPs that are aware of the existence of the risk communications tools and how the tools were accessed (i.e. paper or electronic versions) [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bristol-Myers SquibbPrincetonNew Jersey08540-

Find similar trials in Princeton, NJ

By research site
Bristol-Myers Squibb· Princeton, NJ

Related Studies